Protocol Specific Reserach Support

西蒙斯癌症中心的最高优先事项之一是有效地将科学发现转化为 为了降低癌症发病率和死亡率，德州大学西南部有着悠久的传统 卓越的基础科学和最近的组织明确的癌症中心计划， 在可转化癌症方面， 生物学研究者指导的早期临床研究试验需要大量的监管数据 管理和研究护理资源并不总是通过传统机制提供 以优雅的方式。特定于方案的研究支持提供了一种机制， 将癌症科学应用于临床 这些资金旨在支持西蒙斯癌症中心的计划优先事项。标准 用于评估方案特定研究支持的适用性，包括： 1.投资者发起的可行性/具有特殊科学价值的I期或试点试验 2.试验必须符合以下一项或多项标准： a.要测试的代理或概念是U. T的产品。西南临床前科学。 B.该试验将产生外部同行评审资金或开发成 更大规模的多机构II期或III期试验。 C.该试验促进了基础和临床科学家之间的重要互动， 相关目标 通过每两个月一次的 DOT领导人会议和项目领导人双月会议。信息流 在这些会议上，交通部领导人可以审查投资者提出的协议想法和计划 领导者可以促进试剂或分子准备临床评估。鼓励个别DOT 制定和完善方案概念，以响应癌症中心的优先级，并寻求反馈意见， 临床研究副主任在开发过程的早期。

One of the highest priorities of the Simmons Cancer Center is to efficiently translate scientific discoveries to the clinic in order to reduce cancer morbidity and mortality. U.T. Southwestem has a long tradifion of excellence in the basic sciences and with the recent organizafion of well-defined Cancer Center programs, insfitufional scienfists are responsible for some of the most important recent advances in translatable cancer biology. Early phase Invesfigator-inifiated translafional research trials require significant regulatory, data management and research nursing resources that are not always available through traditional mechanisms in a fimely fashion. Protocol-specific research support provides a mechanism for rapidly translating insfitutional cancer science to the clinic. These funds are intended to support the programmatic priorifies of the Simmons Cancer Center. Criteria used to assess suitability for Protocol-Specific Research support include: 1. Invesfigator-initiated feasibility/Phase I or pilot trial with exceptional scientific merit 2. The trial must meet one or more of the following criteria: a. The agent or concept to be tested is a product of U.T. Southwestern preclinical science. b. The trial will generate data required for external peer-reviewed funding or for development into a larger, multi-institutional phase II or III trial. c. The trial promotes significant interacfion between basic and clinical scienfists to achieve important correlative objecfives. Priorities for this funding are communicated to the Disease Oriented Teams (DOTs) through the bi-monthly DOT leaders meetings and to the Program Leaders at their bi-monthly meefings. Information flows both direcfions at these meefings as DOT leaders can vet invesfigator inifiated protocol ideas and Program leaders can promote agents or molecules ready for clinical evaluafion. Individual DOTs are encouraged to develop and refine protocol concepts responsive to the Cancer Center priorifies and to seek feedback from the Associate Director for Clinical Research early in the development process.